Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products

Published: Thursday, April 12, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Ramcon covers the Northern European countries and serves customers in Denmark, Sweden, Norway, Finland and Iceland with a highly specialized sales force.

Since February of this year Danish Ramcon A/S offers Anagnostics’ drugs of abuse testing and pharmacogenetics solutions as distribution partner.

During the course of the year, further products, especially relating to severe infection testing will follow.

Establishing the innovative products in the Northern European Countries as well as competent and first class customer support are common goals of the partners.

“The decision to partner with Ramcon simply made sense, since Ramcon already specializes in tests and systems for in vitro diagnostics and life sciences with a loyal and broad customer base. Ramcon focuses on first class end-user service and support. Therefore both organizations perfectly fit together”, summarizes Markus Jaquemar, CMO Anagnostics Bioanalysis GmbH.

Jesper Hardt, CEO of Ramcon A/S, is looking forward to a successful partnership: “We can see a clear trend towards multiplex testing. Anagnostics perfectly responds to these market needs with the hyborg system and its testing menu. The fast and efficient response to actual drug consumption will secure access to drug therapy institutions. The efficient and highly sensitive pharmacogenetics test will benefit small or mid-sized pathological entities.”

Multiplex Diagnostics with Focus on Drugs of Abuse Screening, Pharmacogenetics (Oncology) and Serve Infection Testing Anagnostics Bioanalysis with its headquarters in St. Valentin (Austria) is specialized in developing systems, devices and tests in drugs of abuse screening, pharmacogenetics (oncology) and tests for diagnosing severe infections.

With the unique ability to perform protein as well as DNA based assays the hyborg system offers a testing platform meeting needs of personalized medicine and integrated diagnostics.

Anagnostics was established in 2005 by Bernhard Ronacher, a molecular genetics scientist. A cylindrical microarray - the hybcell - is the core of the patented multiplex technology.

Combined with the hyborg analysis system multi-parameter assays are performed in a fully automated manner.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Anagnostics Enters Sales Cooperation with Analis S.A.
Company enters cooperation for Belgium and Luxembourg.
Monday, December 10, 2012
Scientific News
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!